Telix Pharmaceuticals Limited
Telix Pharmaceuticals Limited (TLX.AX) Financial Performance & Income Statement Overview
Review Telix Pharmaceuticals Limited (TLX.AX) income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Telix Pharmaceuticals Limited (TLX.AX) Income Statement & Financial Overview
Review Telix Pharmaceuticals Limited TLX.AX income statement with detailed quarterly and annual figures.
| Metric | Q4 2024 | Q2 2024 | Q4 2023 | Q2 2023 |
|---|---|---|---|---|
| Revenue | $594.24M | $188.96M | $281.71M | $220.83M |
| Cost of Revenue | $208.45M | $65.08M | $57.74M | $130.02M |
| Gross Profit | $385.80M | $123.88M | $223.97M | $90.81M |
| Gross Profit Ratio | $0.65 | $0.66 | $0.80 | $0.41 |
| R&D Expenses | $148.85M | $45.78M | $98.40M | $30.45M |
| SG&A Expenses | $168.61M | $64.25M | $105.50M | $28.93M |
| Operating Expenses | $317.42M | $110.13M | $203.90M | $59.37M |
| Total Costs & Expenses | $525.87M | $175.21M | $261.64M | $189.40M |
| Interest Income | $10.25M | $610000.00 | $566000.00 | $453000.00 |
| Interest Expense | $31.55M | $4.94M | $548000.00 | $442000.00 |
| Depreciation & Amortization | -$2.00M | $2.00M | $3.64M | $3.29M |
| EBITDA | $76.80M | $15.75M | $23.71M | $34.72M |
| EBITDA Ratio | $0.13 | $0.08 | $0.08 | $0.16 |
| Operating Income | $68.38M | $13.75M | $20.07M | $31.44M |
| Operating Income Ratio | $0.12 | $0.07 | $0.07 | $0.14 |
| Other Income/Expenses (Net) | -$21.46M | -$4.61M | -$4.69M | -$43.74M |
| Income Before Tax | $46.91M | $9.14M | $15.39M | -$12.30M |
| Income Before Tax Ratio | $0.08 | $0.05 | $0.05 | -$0.06 |
| Income Tax Expense | $8.67M | -$2.54M | -$4.14M | $2.02M |
| Net Income | $38.24M | $11.68M | $19.53M | -$14.32M |
| Net Income Ratio | $0.06 | $0.06 | $0.07 | -$0.06 |
| EPS | $0.12 | $0.03 | $0.06 | -$0.05 |
| Diluted EPS | $0.11 | $0.03 | $0.06 | -$0.05 |
| Weighted Avg Shares Outstanding | $331.23M | $334.23M | $323.73M | $317.62M |
| Weighted Avg Shares Outstanding (Diluted) | $345.19M | $350.75M | $323.73M | $317.62M |
Over the last four quarters, Telix Pharmaceuticals Limited achieved steady financial progress, growing revenue from $220.83M in Q2 2023 to $594.24M in Q4 2024. Gross profit stayed firm with margins at 65% in Q4 2024 versus 41% in Q2 2023. Operating income totaled $68.38M in Q4 2024, maintaining a 12% margin over recent quarters. Despite shifts in R&D and SG&A costs, EBITDA stayed strong at $76.80M. Net income rose to $38.24M, with EPS at $0.12. Disciplined expense strategies and efficient operations ensured sustained profitability and long-term financial stability.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan